Good Vita / The learning library

DSIP

An experimental peptide associated with sleep-related research discussions.

Educational information only. No medical advice or treatment recommendations.

← Back to the full library

Research compounds Early human study Brain research

Also discussed as: Emideltide, delta sleep-inducing peptide

What it is and how it works

Delta sleep-inducing peptide is a neuropeptide investigated in sleep research. Its name reflects a research hypothesis; a suggestive name is not a clinical result. The selected human study is useful because it tests a sleep-related outcome rather than relying on the name.

Source for the mechanism context →

A closer look at the cited evidence

Early human study

This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.

Study or assessment
1987 — DSIP short-term study in chronic insomnia
Design
Short-term study including double-blind placebo nights.
Who or what was studied
People with chronic insomnia.
What was observed
The reported sleep measures did not differ significantly from baseline or double-blind placebo nights.
Limits of interpretation
This small historical study does not establish long-term efficacy or safety. It should not be treated as a complete account of all sleep research.
Read the cited study or assessment →

What the evidence means

A name suggesting sleep effects does not establish a treatment for insomnia.

Approval and regulatory context

Not an FDA-approved sleep medicine.

Safety and uncertainty

Route-specific safety information is lacking.

What remains uncertain

A broad insomnia-treatment claim would require reproducible, clinically meaningful human results. The evidence should identify the population, sleep outcomes, duration, and harms instead of inferring an effect from the compound’s name.

These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.

Sources behind this overview

Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.

Start Your Assessment